112 related articles for article (PubMed ID: 26954624)
1. Effect of N-Terminal Acylation on the Activity of Myostatin Inhibitory Peptides.
Takayama K; Nakamura A; Rentier C; Mino Y; Asari T; Saga Y; Taguchi A; Yakushiji F; Hayashi Y
ChemMedChem; 2016 Apr; 11(8):845-9. PubMed ID: 26954624
[TBL] [Abstract][Full Text] [Related]
2. Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition.
Takayama K; Noguchi Y; Aoki S; Takayama S; Yoshida M; Asari T; Yakushiji F; Nishimatsu S; Ohsawa Y; Itoh F; Negishi Y; Sunada Y; Hayashi Y
J Med Chem; 2015 Feb; 58(3):1544-9. PubMed ID: 25569186
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of potent myostatin inhibitory cyclic peptides.
Rentier C; Takayama K; Saitoh M; Nakamura A; Ikeyama H; Taguchi A; Taniguchi A; Hayashi Y
Bioorg Med Chem; 2019 Apr; 27(7):1437-1443. PubMed ID: 30777663
[TBL] [Abstract][Full Text] [Related]
4. Strategic structure-activity relationship study on a follistatin-derived myostatin inhibitory peptide.
Saitoh M; Takayama K; Roppongi Y; Shimada T; Taguchi A; Taniguchi A; Hayashi Y
Bioorg Med Chem Lett; 2021 Aug; 46():128163. PubMed ID: 34087433
[TBL] [Abstract][Full Text] [Related]
5. Development of Potent Myostatin Inhibitory Peptides through Hydrophobic Residue-Directed Structural Modification.
Takayama K; Rentier C; Asari T; Nakamura A; Saga Y; Shimada T; Nirasawa K; Sasaki E; Muguruma K; Taguchi A; Taniguchi A; Negishi Y; Hayashi Y
ACS Med Chem Lett; 2017 Jul; 8(7):751-756. PubMed ID: 28740611
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for the Effective Myostatin Inhibition of the Mouse Myostatin Prodomain-Derived Minimum Peptide.
Asari T; Takayama K; Nakamura A; Shimada T; Taguchi A; Hayashi Y
ACS Med Chem Lett; 2017 Jan; 8(1):113-117. PubMed ID: 28105285
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a follistatin-derived myostatin inhibitory peptide.
Saitoh M; Takayama K; Hitachi K; Taguchi A; Taniguchi A; Tsuchida K; Hayashi Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126892. PubMed ID: 31874826
[TBL] [Abstract][Full Text] [Related]
8. Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin.
Asari T; Ikeyama H; Taguchi A; Taniguchi A; Hayashi Y; Takayama K
Bioorg Med Chem; 2021 Jun; 40():116181. PubMed ID: 33957441
[TBL] [Abstract][Full Text] [Related]
9. Identification of the minimum region of flatfish myostatin propeptide (Pep45-65) for myostatin inhibition and its potential to enhance muscle growth and performance in animals.
Kim JH; Kim JH; Sutikno LA; Lee SB; Jin DH; Hong YK; Kim YS; Jin HJ
PLoS One; 2019; 14(4):e0215298. PubMed ID: 30998775
[TBL] [Abstract][Full Text] [Related]
10. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y
PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides.
Takayama K; Odagiri M; Taguchi A; Taniguchi A; Hayashi Y
Chem Pharm Bull (Tokyo); 2020; 68(6):512-515. PubMed ID: 32475853
[TBL] [Abstract][Full Text] [Related]
12. Myostatin inhibitory region of fish (Paralichthys olivaceus) myostatin-1 propeptide.
Lee SB; Kim JH; Jin DH; Jin HJ; Kim YS
Comp Biochem Physiol B Biochem Mol Biol; 2016; 194-195():65-70. PubMed ID: 26827850
[TBL] [Abstract][Full Text] [Related]
13. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
14. Development of functionalized peptides for efficient inhibition of myostatin by selective photooxygenation.
Okamoto H; Taniguchi A; Usami S; Katsuyama M; Konno S; Taguchi A; Takayama K; Hayashi Y
Org Biomol Chem; 2021 Jan; 19(1):199-207. PubMed ID: 33174572
[TBL] [Abstract][Full Text] [Related]
15. [Medicinal Chemistry Focused on Mid-sized Peptides Derived from Biomolecules].
Takayama K
Yakugaku Zasshi; 2019; 139(11):1377-1384. PubMed ID: 31685733
[TBL] [Abstract][Full Text] [Related]
16. Targeting myostatin for therapies against muscle-wasting disorders.
Tsuchida K
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
[TBL] [Abstract][Full Text] [Related]
17. Myostatin - From the Mighty Mouse to cardiovascular disease and cachexia.
Dschietzig TB
Clin Chim Acta; 2014 Jun; 433():216-24. PubMed ID: 24680839
[TBL] [Abstract][Full Text] [Related]
18. Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice.
Takayama K; Asari T; Saitoh M; Nirasawa K; Sasaki E; Roppongi Y; Nakamura A; Saga Y; Shimada T; Ikeyama H; Taguchi A; Taniguchi A; Negishi Y; Hayashi Y
ACS Med Chem Lett; 2019 Jun; 10(6):985-990. PubMed ID: 31223459
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides.
Okamoto H; Taniguchi A; Usami S; Taguchi A; Takayama K; Hayashi Y
Chem Commun (Camb); 2019 Aug; 55(62):9108-9111. PubMed ID: 31298230
[TBL] [Abstract][Full Text] [Related]
20. Influence of acylation of a Peptide corresponding to the amino-terminal region of endothelial nitric oxide synthase on the interaction with model membranes.
Yélamos B; Roncal F; Albar JP; Rodríguez-Crespo I; Gavilanes F
Biochemistry; 2006 Jan; 45(4):1263-70. PubMed ID: 16430222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
